Clinical Trials for Breast Cancer

201405031

An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations Phase II Principal Investigator Park, Haeseong Disease Site Brain and Nervous System; Lung Learn more about this…

201407100

A PHASE 1B CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNE RESPONSE TO A MAMMAGLOBIN-A DNA VACCINE IN ER+, HER2- BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT ENDOCRINE THERAPY OR CHEMOTHERAPY Phase I Principal Investigator Gillanders, William…

201503010

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Phase II/III Principal Investigator Zoberi, Imran Disease Site Breast Learn more…

201604023

PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL Phase III Principal Investigator Zoberi, Imran Disease Site…

201611010

Endocrine Treatment Alone as Primary Treatment for Elderly Patients with Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Phase II Principal Investigator Aft, Rebecca Disease Site Breast Learn more about this study at:…

201701042

A Phase II Open-Label,Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-LI Therapy (atezolizumab;MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Phase II Principal Investigator Park, Haeseong…

201704073

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer (EAI142) Phase II Principal Investigator Dehdashti, Farrokh Disease Site Breast Learn more about this study at:…

201710148

A Multi-Center, Open-Label, Phase 1/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients with Advanced Solid Tumors Phase I Principal Investigator Park, Haeseong Disease Site Anus; Brain and…

201812035

RNA Disruption Assay (RDA) – Breast cancer Response EValuation for Individualized TherapY (BREVITY) Phase N/A Principal Investigator Ademuyiwa, Foluso Disease Site Breast Learn more about this study at: clinicaltrials.gov

201902108

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative…

201902119

Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) in patients with metastatic triple negative breast cancer Phase II Principal Investigator Gillanders, William Disease Site Breast…

201905026

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Phase N/A Principal Investigator Haroutounian, Simon Disease Site Breast; Hodgkin’s Lymphoma; Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201905083

Mammaprint, BluePrint and Full genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) Phase N/A Principal Investigator Ma, Cynthia Disease Site Breast Learn more about this study…

201908073

Randomized, double-blind, phase 3 of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer Phase III Principal Investigator Frith, Ashley Disease Site Breast Learn…

201909214

Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy induced peripheral neuropathy in African American women Phase II Principal Investigator Rearden, Timothy Disease Site Breast Learn more about this study…

201911082

A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA) Phase I/II…

202001160

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors Phase I (Cancer Control) Principal Investigator Govindan, Ramaswamy Disease Site…

202003106

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)…

202004058

A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study Phase II Principal Investigator Clifton,…

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…

202006070

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor…

202006122

BR-076: A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer Phase II (Cancer Control) Principal Investigator…

202006136

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors Phase…

202007016

Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer Phase I/II Principal Investigator Opyrchal, Mateusz Disease Site Breast Learn more…

202007074

A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer, who have received prior hormonal…

202007216

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non- Breast Cancers Phase I Principal…

202008031

A PHASE 1/2 OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ZN-c5 ALONE AND IN COMBINATION WITH PALBOCICLIB IN SUBJECTS WITH ESTROGEN-RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 NEGATIVE…

202009029

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigators Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)…

202009136

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment…

202010089

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer Phase I/II Principal Investigator Bagegni, Nusayba Disease Site Breast Learn more about…

202102117

The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib…

202103081

Phase 2 Study of FLX475 in Combination with Ipilimumab in Advanced Melanoma Phase II Principal Investigator Johanns, Tanner Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov

202104085

Evaluation of Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma Phase N/A Principal Investigator Zoberi, Imran Disease Site Breast Learn more about…